Cellular metabolism is a tightly controlled process in which the cell adapts fluxes through metabolic pathways in response to changes in nutrient supply. Among the transcription factors that regulate gene expression and thereby cause changes in cellular metabolism is the basic leucine-zipper (bZIP) transcription factor CCAAT/enhancer-binding protein alpha (C/EBPα). Protein lysine acetylation is a key post-translational modification (PTM) that integrates cellular metabolic cues with other physiological processes. Here we show that C/EBPα is acetylated by the lysine acetyl transferase (KAT) p300 and deacetylated by the lysine deacetylase (KDAC) Sirtuin1 (SIRT1). SIRT1 is activated in times of energy demand by high levels of nicotinamide adenine dinucleotide (NAD + ) and controls mitochondrial biogenesis and function. A hypoacetylated mutant of C/EBPα induces the transcription of mitochondrial genes and results in increased mitochondrial respiration. Our study identifies C/EBPα as a key mediator of SIRT1-controlled adaption of energy homeostasis to changes in nutrient supply.
INTRODUCTION
96 enzymatic activity and therefore are activated in times of energy demand when NAD + levels are high (high NAD + /NADH ratio) (Houtkooper et al., 2012) .
Involvement of KATs in C/EBPα mediated transcription has been reported in the past (Bararia et al., 2008; Erickson et al., 2001; Jurado et al., 2002; Yoshida et al., 2006) , however, the role C/EBPα protein lysine acetylation in the transcriptional regulation of metabolic genes has not been addressed. Since C/EBPα is a key regulator of metabolism we hypothesized that reversible acetylation of C/EBPα is decisively involved in regulating metabolic homeostasis. Here we show that C/EBPα is acetylated on lysines K159 and K298 by the KAT p300, which modulates the transcriptional activity of C/EBPα. We show that acetylation of C/EBPα is dependent on glucose availability and we identify SIRT1 as the sole sirtuin that mediates NAD + -dependent deacetylation of C/EBPα. A hypoacetylated mutant of C/EBPα induces the expression of genes involved in the function of the mitochondrion and oxidation-reduction processes, which is accompanied by an increase in mitochondrial mass and cellular oxygen consumption rates. Our study shows that reversible acetylation of C/EBPα in response to changed metabolic conditions alters its transcriptional function to adapt metabolic gene expression and plays an important role in SIRT1-controlled cellular metabolic homeostasis.
RESULTS

Acetylation of C/EBPα by p300 enhances its transactivation activity
The presence of fifteen conserved lysines in sequences of vertebrate C/EBPα orthologs suggests that C/EBPα is a potential target for lysine acetylation ( Figure S1 ). Glucoserich cell culture conditions are known to increase protein-acetylation through increased availability of acetyl-CoA as substrate for KATs to donate an acyl group to the target lysine (Shi and Tu, 2015) . Acetylation of endogenous C/EBPα in lysates from the Fao rat hepatoma cell line was detected using an anti-acetylated lysine (anti-Ac-K) antibody following immunoprecipitation (IP) of C/EBPα under high glucose (25 mM) conditions, which was reduced under low glucose (5 mM) conditions ( Figure 1A ).
Acetylation of immunoprecipitated C/EBPα was also detected in HEK293T cells lacking endogenous C/EBPα that were transfected with a C/EBPα expression vector ( Figure 1B ). Next we investigated whether co-expression of the four major KATs, p300, P/CAF, GCN5 or Tip60 alter the transcriptional activity of C/EBPα using a luciferasebased reporter solely containing two natural C/EBP-binding sites of the cMGF promoter (Sterneck et al., 1992) . Co-transfection with p300 resulted in an increase in C/EBPα-induced promoter activity in a dose dependent manner whereas cotransfection with the other KATs had no significant effect (Figures 1C, D and S2A) . To investigate a direct interaction between C/EBPα and p300 as well as three additional major KATs we co-expressed C/EBPα with p300-HA, P/CAF-FLAG, Tip60 in HEK293T cells and performed co-immunoprecipitation experiments using anti-C/EBPα antibodies. C/EBPα co-precipitated with p300, P/CAF, GCN5, but not with Tip60 ( Figure S2B ), which was confirmed by reciprocal, co-immunoprecipitation of the C/EBPα with the same KATs ( Figures 1E and S2C ). To examine whether the intrinsic KAT function of p300 is involved in C/EBPα acetylation and transactivation potential, we co-expressed C/EBPα with either p300 or p300 with its KAT-domain deleted (p300ΔKAT-HA) and analyzed C/EBPα acetylation and p300 binding by C/EBPα co-immunoprecipitation. C/EBPα acetylation was abolished by expression of p300ΔKAT-HA ( Figure 1F ). In addition, the p300 dependent C/EBPα transactivation activity is abrogated by deletion of the p300-KAT ( Figure 1D ). In addition, p300mediated acetylation of C/EBPα in HEK293 cells is strongly reduced under low glucose conditions (5 mM), confirming that protein acetylation is facilitated under conditions of high acetyl-CoA availability ( Figure 1G ). Moreover, in Fao cells acetylation of endogenous C/EBPα was abolished by treatment with the p300 inhibitor C646 ( Figure   1H ). Therefore, we propose that p300 catalyzes the acetylation of C/EBPα and thereby alters its transcriptional function.
Figure 1. Acetyla tion of C/EBP α by p300 enhances its transa ctivation activity. (A)
Immunoblot ana lysis of im munoprecipita ted (IP) C/E BPα a nd tota l lysates (In pu t) of Fa o cells cu ltu red overnigh t in either h igh (25 mM) or low (5 mM) glucose med ium. An tib ody sta ining as in dicated. (B) Immunob lot ana lys is of immunoprecip itated (IP) C/EBPα and total lys ates (In pu t) of HEK293T cells ectop ica lly ex press ing C/EBPα or empty vector (E.V.) con trol. A ntibody sta in in g as indica ted. (C) HEK293T cells w ere trans iently trans fected with C/EBP -respon sive firefly -rep orter vector, a renilla exp ression vector for n ormalization, C/EBPα an d/or one of the lys in e s a cetyl tra nsferases (KATs) ex press in g vector as ind ica ted . Lu ciferase activity was meas ured 48 h later (n =4). (D) HEK293T cells w ere tra n siently tran sfected w ith lu ciferas e C/EBP -res pon sive fireflyrep orter vector, renilla expres sion vector for normalization, C/EBPα and increa sed amou nts of either w t p300 -HA or ΔKATp300 -HA (p300 with its lys in e acetyl tran sfera se d oma in deleted) express ion vectors. Luciferase activity was measu red 48 h later (n=4 ). (E) Immunoblot ana lysis of HA -immunoprecipita ted (IP ) p30 0 -HA and tota l lys ates (In put) of HEK293T cells ectop ica lly exp res sing C/EBPα a nd p300 -HA or empty vector (EV ) con tr ol. Antibod y s ta ining as in dicated . (F) Immunoblot ana lys is of immunoprecip itated (IP) C/EBPα and total lysa tes (I npu t) of HEK293T cells ectopically exp ress ing C/EBPα a nd p300 -HA or ΔKATp300 -HA. Antibody stain ing as indica ted. (G) Immunoblot a nalys is of im munoprecip itated (IP) C/EBPα and total lysa tes (In pu t) of HEK293T cells ectop ica lly exp ress ing C/EBPα an d p300 -HA or empty vector (E.V.) con trol, an d cultu red overn ight in either high (25 mM) or low (5 mM) glu cos e medium. Antibod y s tainin g as indica ted. (H) Immunob lot a nalys is of im munoprecipita ted (IP) C/EBPα and tota l lysa tes (Inp ut) of Fa o cells cells treated overn ight with either DMS O or p300 in hib itor (C646, 10 μM). Antib ody sta ining a s ind ica ted. S ta tistical differences were ana lyzed by S tud en t's t -tes ts. Error ba rs rep res en t ±SD, ***P<0 . 001, NS: not s ignifican t.
Lysine (K) 298 of C/EBPα was recently identified as an acetylation site using the anti-Ac-K298-C/EBPα antibody (Bararia et al., 2016) . Using this antibody, a co-expression experiment with p300 in HEK293T cells showed that K298 of C/EBPα is also acetylated by p300 ( Figure S2D ). In addition, both the endogenously expressed C/EBPα isoforms p42 and p30 (Calkhoven et al., 2000) in Fao cells are acetylated at K298, which is dependent on high glucose conditions ( Figure S2E ). Changes in nutrient and calorie intake can influence acetylation of regulatory proteins through changes in cellular concentrations of Acetyl-CoA and NAD+ (Houtkooper et al., 2012; Verdin and Ott, 2015) . To examine C/EBPα acetylation under different metabolic conditions in vivo we analyzed livers from mice that were either subject of calorie restriction (CR; 4 weeks) or high fat diet (HFD; 20 weeks). By using anti-Ac-K298-C/EBPα we found a decrease in C/EBPα K298-acetylation in livers of CR mice and an increase of its acetylation in livers of HFD mice ( Figure S2F and S2G; shown is the p30-C/EBPα). Taken together, our data show that C/EBPα acetylation changes with nutritional status in vivo.
The immunoprecipitation experiments described above do not reveal to what extend or which of the lysines in C/EBPα are acetylated by p300 beyond K298. To examine the distribution of lysine-acetylation, we purified acetylated C/EBPα protein derived from HEK293T cells co-expressing C/EBPα and p300 and examined protein acetylation by mass-spectrometric analysis (Figure 2 ). Of the fifteen lysines in C/EBPα, eleven were covered by the analyzed peptides of which five (K159, K250, K273, K275, K276) were found acetylated and six (K92, K169, K280, K304, K313, K352) not acetylated ( Figure 2 ). Taken together, our analyses suggest that C/EBPα is subject of extensive acetylation mediated by p300 and that acetylation enhances its transactivation activity.
Figure 2. C/EBPα is acetyla ted by p300 a t mult i p le lys ines.
Mass spectrometry ana lyses id entify the C/E BPα acetyla tion s ites in HEK293T cells tran sfected with exp ression pla smids for C/EBPα and p300-HA. Ma scot scores (u pper pa nel) > 40 were most con fiden t for the true detection of acetylation. The low e r gra ph rep resen ts th e C/EBP α protein with th e a cetyla tion sta tus of its 15 lys ines a nd loca tions of th e tra nsa ctiva tion domain s (TAD ), DNA -b ind ing d omain (D BD) and Leucine -zip p er dimerization d omain (L ZIP).
C/EBPα binds to and is deacetylated by SIRT1
Lysine acetylation is a reversible PTM, which implies that specific lysine deacetylases (KDACs) may be responsible for C/EBPα deacetylation. The dependence of C/EBPα acetylation on glucose ( Figure 1A and 1G) and the fact that C/EBPα and sirtuins both regulate glucose and fatty acid metabolism suggested that the NAD + -dependent sirtuin deacetylases (SIRTs) could be involved. We examined the potential involvement of the four cytoplasmic and nuclear sirtuins, SIRT1, -2, -6 and -7 as well as SIRT3 that is mainly mitochondrial, however, may have nuclear functions in addition (Houtkooper et al., 2012) . The mitochondrial SIRT4 and SIRT5 that can act both in the mitochondria and cytosol (Nishida et al., 2015; Park et al., 2013) were not tested. To examine possible C/EBPα-sirtuin interactions C/EBPα was co-expressed together with one of the FLAG-tagged sirtuins in HEK293T cells. Coimmunoprecipitation using an anti-C/EBPα antibody followed by immunoblotting with an anti-FLAG antibody revealed that only SIRT1 interacts with C/EBPα ( Figure   3A ). The interaction between C/EBPα and SIRT1 was confirmed by reciprocal coimmunoprecipitation using an anti-FLAG antibody ( Figure 3B ). Next we examined the capacity of SIRT1 to deacetylate C/EBPα. HEK293T cells were co-transfected by C/EBPα and p300 expression plasmids to obtain acetylated C/EBPα in the presence of either SIRT1 or SIRT2 expression plasmids or empty vector control. Following C/EBPα immunoprecipitation, immunoblotting with an anti-HA or anti-Ac-K antibody showed binding to p300 and high level of C/EBPα acetylation, respectively, which are abrogated by co-expression of SIRT1 ( Figure 3C ). Co-expression of SIRT2, which does not interact with C/EBPα, has no effect on C/EBPα acetylation ( Figure 3C ). In addition, the ASEB computer algorithm (http://bioinfo.bjmu.edu.cn/huac/) (Wang et al., 2012) for prediction of SIRT1-mediated deacetylation lists all the mass-spectrometric identified lysines and K298 as potential SIRT1 deacetylation sites (Table S1 ).
Furthermore, a progressive increase in expression levels of SIRT1 resulted in a progressive decrease in the acetylation level of C/EBPα ( Figure 3D ), which is accompanied by a progressive decrease in p300-dependent C/EBPα transactivation potential ( Figure 3E ). (C) Immunoblot a nalys is of immunoprecip itated (IP ) C/EBPα and tota l lysa tes (Inp ut) of HEK293T cells ectopically ex p res sing C/E BPα and p300 -HA, and SI RT1 -FLAG or SI RT2-FLA G. Antibod y s ta ining as in dicated . (D) Immunoblot ana lysis of immunoprecip itated (IP) C/EBPα and total lysa tes (I npu t) of HEK293T cells ectop ica lly express ing C/EBPα an d p300 -HA, a nd increas ed amoun ts of SI RT 1 -FLAG. Antib ody s taining as ind ica ted . (E) HEK293T cells trans fected with lucifera se C/E BPα resp ons ive promoter vector, renilla express ion vector for n orma lization, C/EBPα, p300 -HA an d increa sed amounts of SI RT 1 express ion vectors as in dicated. Luciferase activity wa s meas ured 48 h later (n =3). S tatis tical differences were an alyzed b y Stud ent' s t -tes ts. Error ba rs rep res en t ±SD, *P <0.05, **P<0.01 , ***P <0. 001. NS: n ot s ignifica nt. (F) In vitro SIRT1-dea cetyla tion as say for C/EBPα. C/EBPα -FL AG and SIRT1 -FLAG proteins were purified from HEK293 cel ls by immunoprecip ita tion with an ti -FLAG M2 b eads. Th e ind icated proteins were in cuba ted a t 3 0 °C for 1 h w ith NAD + or NA M where in dicated, followed by immunoblotting with anti -acetyla ted lys ine, an ti -C/EBPα an d anti-FLAG an tibod ies.
To examine whether C/EBPα-deacetylation by SIRT1 is attributed to the enzymatic activity of SIRT1 we set up an in vitro deacetylation assay. Purified FLAG-tagged acetylated C/EBPα was obtained by anti-FLAG-IP from HEK293T cells that were cotransfected with C/EBPα-FLAG and p300 expression plasmids. Purified FLAG-tagged SIRT1 was obtained separately by anti-FLAG-IP from HEK293T cells transfected with a SIRT1-FLAG expression plasmid. The deacetylation reaction assay revealed that SIRT1 efficiently deacetylates C/EBPα in the presence of NAD + in vitro ( Figure 3F ).
Moreover, the deacetylation of C/EBPα by SIRT1 was inhibited in the presence of the sirtuin inhibitor nicotinamide (NAM). Taken together, our data show that lysine residues in C/EBPα can be deacetylated by SIRT1.
Acetylation of C/EBPα does not alter its subcellular localization or DNAbinding
Lysine acetylation of a transcription factor may serve to alter its transcriptional function, its DNA-binding properties or its subcellular localization (Choudhary et al., 2014) . We first examined whether the presence of either p300 or SIRT1 alters the subcellular localization of C/EBPα. Immunofluorescent staining of C/EBPα in HEK293T cells showed no difference in its nuclear localization between hyperacetylated C/EBPα derived from cells co-expressing p300 or hypoacetylated C/EBPα derived from cells co-expressing SIRT1 ( Figure 4A and S3A). To determine whether co-expression of p300 or SIRT1 alters the binding of C/EBPα to a DNA recognition sequence purified (IP) FLAG-tagged C/EBPα wt was incubated with DNA oligonucleotide probes of either a C/EBP-consensus sequence or a mutated sequence and DNA-protein complexes were analyzed in an electrophoretic mobility shift analyses (EMSAs). SYBR Green DNA and SYPRO Ruby protein staining revealed that there is no difference in the DNA binding of C/EBPα between cells co-expressing p300 or co-expressing SIRT1 ( Figure 4B ). No DNA binding was detected with the C/EBPαmutated binding sites. These data show that acetylation status of C/EBPα does not affect DNA binding in a significant way.
To examine the involvement of acetylation of individual C/EBPα lysines on the transactivation activity of C/EBPα we generated mutations that either mimic acetylation (Lysine (K) to Glutamine (Q)) or non-acetylation (Lysine (K) to Arginine (R)) at the acetylated lysines identified by mass spectrometry, K159, K250, K273, K275, K276 and the established acetylation site K298. Figure 4C shows that only the single K159Q or K298Q acetylation mimicking mutations in C/EBPα result in enhanced C/EBPα transactivation capacity compared to the wt C/EBPα, using the C/EBP-binding site reporter. None of the K-to-R acetylation preventing mutations altered the reporter activity ( Figure 4D ).
Next we examine subcellular localization of the dual K159Q/K298Q acetylation mimicking and K159R/K298R non-acetylation mutants of C/EBPα. Neither mutation affected the subcellular localization ( Figure 4E ). In addition, the mutations do not affect DNA binding in an EMSA ( Figure 4F ). Furthermore binding to the C/EBPbinding site in the reporter was not altered by the lysine mutations as was measured by C/EBPα-immunoprecipitation and qRT-PCR quantification of bound DNA ( Figure   4G and S2B). Finally, chromatin-immunoprecipitation (ChIP) experiments showed that there is no difference in binding between wt C/EBPα, the K159Q/K298Q C/EBPα mutant or K159R/K298R C/EBPα mutant to natural C/EBP binding sites in promoters of the endogenous genes G-CSFR and PEPCK1 (Figures 4H and Figure S3B ).
Figure 4. Acetyla tion of C/EBPα does not a lter its subce llu la r loca lization or DNA -binding (A)
HEK293T cells tran sfected w ith C/E BPα alone, C/EBPα w ith p300 -HA or C/EBPα w ith SIRT 1 -FLAG ex press ion vectors. Immunoh is tochemistry was performed us ing a nti -C/EBPα, an ti-H A and anti-FLAG an tib od ies. D NA was s tained with DAPI to visu alize the nu cleus. Scale b ars s ize is 10 μm. See F igure S2A for a cetyla tion sta tu s of C/EBPα. (B) HEK293T cells trans fected with C/EBPα -FLAG alone, C/EBPα -FLAG with p300 -HA or C/EBPα-FLAG with SIRT1 exp res s ion vectors. C/EBPα -FLAG protein was pu rified by immunoprecip ita tion with a nti -FLAG M2 b ead s. E MSA w as performed us ing a double -stran d ed oligonu cleotid es conta in ing either w t or mu tated (mt) C/EBPα binding site.
(C) and ( D) HEK293T cells w ere tra nsien tly trans fected w ith C/EBP -resp ons ive lucifera se rep orter, renilla exp res sion vector for normalization, w t C/EBPα or eith er (C) lys ine to glutamine (KQ ) or (D) lys in e to a rgin in e (KR) mu tated C/EBP α ex press ion vectors. L ucifera se activity wa s mea sured 48 h later (n =3). Sta tis tical d ifferen ces were ana lyzed b y S tud en t's ttes ts. Error ba rs rep resen t ±S D, *P<0. 05, **P <0.01, ***P<0. 001. NS: not s ignifican t. (E) HEK293T cells w ere trans iently tran sfected with wt, K1 59/298Q or K159/298 R mu ta ted C/EBPα-FLAG express ion vectors. Immunohis toch emis try w as performed using anti -FLA G antibody. DNA wa s s ta ined with DAPI to vis ualize th e nu cleus . Sca le bars s ize is 10 μm. (F) HEK293T cells w ere trans iently tran sfected w ith w t, K1 59/298Q or K159/298R muta ted C/EBPα-FLAG exp res sion vectors. C/EBPα proteins w ere p urified b y immunop recip itation with anti-FLAG M2 bea ds.
EMSA wa s p erformed u sing a d ouble -strand ed oligonu cleotides con taining eith er wt or muta ted (mt) C/EBPα b in ding site. Therefore we conclude that acetylation of the lysines K159/K298 enhanced C/EBPα transactivation without affecting subcellular localization or DNA-binding.
Acetylation of Lysine 298 of C/EBPα stimulates acetylation of subsequent lysines
Next we asked whether prevention of acetylation of either K159, K298 or of all six lysines by K-to-R mutations affects p300-binding and acetylation or the transactivation potential of C/EBPα. K-to-R mutated C/EBPα mutants were coexpressed with p300 in HEK293T cells and p300-binding and C/EBPα-acetylation was analyzed after C/EBPα immunoprecipitation. Notably, the mutation K298R strongly reduced binding to p300 associated with a strong reduction in C/EBPα acetylation ( Figure 5A ). The K159R single mutation had no effect on p300-binding and C/EBPαacetylation, although in the double mutant K159/298R the level of C/EBPα-acetylation is further decreased ( Figure 5A ). As expected, mutation of all six lysines (K159/250/273/275/276/298) in the K6R mutant reduces C/EBPα acetylation by p300 to very low levels. In accordance, the transactivation of the C/EBP-reporter is similar for co-expression of wt-or K159R-C/EBPα, decreased for K298R-C/EBPα and further decreased for K159/298R-and K6R-C/EBPα ( Figure 5B ). Complementary results were obtained with the opposite lysine-acetylation mimicking K-to-Q mutations. The K159Q mutant did not significantly improve binding of C/EBPα to p300 or C/EBPα-acetylation while with the K298Q mutant p300-binding and C/EBPα-acetylation is strongly increased, and there is a further increase for the double mutant K159/298Q ( Figure 5C ). The K6Q mutation also results in enhanced binding of p300 and a stronger acetylation signal although the anti-L-Ac antibody does not recognize the KQ mutations. This suggests that in the K6Q mutant, acetylation of other lysines increases that normally are not efficiently acetylated. Coexpression of the K-to-Q C/EBPα mutants, p300 and the luciferase C/EBP-reporter resulted in a gradual increase in reporter activity from K159Q-to K298Q-to K159/298Q-and K6Q-C/EBPα ( Figure 5D ). Finally, increasing amounts of SIRT1 coexpression does not reduce the transactivation potential through deacetylation of either K159/298Q-or K6Q-C/EBPα ( Figure S4 ). Together, these results suggest that K298-acetylation is a priming acetylation event stimulating the recruitment of p300, acetylation of K159 and further acetylation of C/EBPα.
C/EBPα acetylation status determines the C/EBPα-regulated transcriptome
To investigate the consequences of C/EBPα-acetylation on global C/EBPα-controlled gene transcription we generated Hepa1-6 mouse hepatoma cell lines with cumateinducible expression of wt-, K159Q/K298Q-or K159R/K298R-C/EBPα-FLAG proteins ( Figure 6A ). Comparative transcriptome analysis identified 110 upregulated transcripts and 122 downregulated transcripts in the hypoacetylation K159R/K298R-C/EBPα mutant versus hyperacetylation K159Q/K298Q-C/EBPα mutant expressing cells ( Figure 6B) . We only considered genes to be differential regulated between the hypo- Figure 6D and Table S2 ). Most of the regulated genes have C/EBPβ-associated DNA fragments in the ENCODE database (http://genome.ucsc.edu/ENCODE/) (Table S2 ). C/EBPβ is closely related to C/EBPα and since they bind to the same recognition sequences C/EBPβ may substitute for C/EBPα for which data are not available. In the metabolic context these results suggest that deacetylation of C/EBPα is involved in the SIRT1 controlled increase in mitochondrial biogenesis and function under conditions of low glucose / low energy.
Hypoacetylated C/EBPα enhances mitochondrial function
In line with a role of hypoacetylated C/EBPα in mitochondrial regulation we found that cumate-induction of the K159R/K298R-C/EBPα mutant in Hepa 1-6 cells that are cultured in acetylation-favoring high glucose medium results in increased accumulation of MitoTracker fluorescent dye as a measure for mitochondrial mass, compared to the hyperacetylation K159Q/K298Q-or wt-C/EBPα (Figures 7A and S5A ).
In addition, under low glucose deacetylation-favoring conditions (2.5 mM) wt reaches similar mitochondrial mass compared to hypoacetylation K159R/K298R-C/EBPα, while the acetylation mimicking K159Q/K298Q-C/EBPα fails to increase mitochondrial mass ( Figure 7A ). The relative mitochondrial DNA (mtDNA) copy number did not changes upon expression of the C/EBPα variants ( Figure S5B ). To examine whether C/EBPα is required for SIRT1-dependent induction of mitochondrial mass we stimulated SIRT1 activity by treatment with SIRT1 activator II and compared mitochondrial mass of cells with sh-C/EBPα knockdown to control sh-RNA.
Treatment with SIRT1 activator II resulted in a clear increase in mitochondrial mass in control cells that was almost completely abrogated in C/EBPα knockdown cells ( Figure 7B ). Taken together these data show that deacetylation of C/EBPα is required for the SIRT1 induced increase in mitochondrial mass. Figure 7E and S5E) . Induction of the hypoacetylation K159/298R-C/EBPα did not increase ECAR compared to wt C/EBPα, while the K159/298Q-C/EBPα mutant mildly decreased the maximal ECAR ( Figure 7F and S5F) .
These data indicate that induction of respiration by C/EBPα requires its lysine residues either to be available for deacetylation or being mutated to mimic hypoacetylation.
To test whether SIRT1 activation is required for the induction of respiration by wt C/EBPα under low glucose conditions the cells were treated with the SIRT1 inhibitor Ex-527 (Selisistat), which completely inhibited the wt C/EBPα-induced basal OCR, maximal OCR and SRC under the low (2.5 mM) glucose deacetylation-favoring condition ( Figures 7G and S5G ).
Taken together, our data suggest that deacetylation of C/EBPα is part of the SIRT1controlled increase in mitochondrial biogenesis and function. 
DISCUSSION
In this study, we demonstrate that C/EBPα is acetylated by p300 and deacetylated by SIRT1 and that the acetylation status of C/EBPα determines its transcriptional functions. By using acetylation mimicking (KQ) or acetylation preventing (KR) mutations our data suggest that acetylation of lysine residue K298 primes for p300catalyzed acetylation at various additional lysines and that the K159/298Q dual mutation can substitute for maximal acetylation levels. We show that the acetylation The results of the transcriptome analysis revealing differential up-or downregulation of distinct endogenous genes by the hypoacetylated K159/298R-C/EBPα mutant versus the hyperacetylated K159/298Q-C/EBPα mutant ( Figure 6B) is seemingly contradictory to the results obtained with the naked (non-chromatinized) promoterreporter assays. The reporter used in our study is activated by wt C/EBPα and its activation is further increased by co-transfection of p300 ( Figure 1D) . The reporter is also strongly activated by the transfection of hyperacetylated K298Q-C/EBPα ( Figure   4C and D) or K159/298Q-C/EBPα mutants ( Figure 5B and D) , while the effect of the hypoacetylated K298R-and K159/298R-C/EBPα mutants is similar to wt C/EBPα in the absence of p300 and inhibitory in the context of p300 co-transfection. This suggests that acetylation of C/EBPα increases its transcriptional activity, but it also shows that hypoacetylated K298R-and K159/298R-C/EBPα mutants still have a transactivation potential that is similar to wt C/EBPα in the absence of p300. Promoter-reporters have the limitation that the readout is determined by a selected naked DNA-fragment; in our case it solely contains two natural C/EBP-binding sites of the cMGF promoter (Sterneck et al., 1992) . Therefore, they cannot fully substitute for the more complex regulation of endogenous transcription that is influenced by chromatin modifiers and by other transcription factors that bind at the promoter and enhancer regions.
Although we do not know whether the observed changes in the transcriptome are a result of direct promoter regulation through C/EBPα or of an indirect effect, the presence of C/EBP binding sites in most of the genes speaks in favor of direct regulation (Table S3 ). Thus, the acetylation state of C/EBPα might discriminate between interaction partners and/or co-factors and thereby affect different endogenous promoters in opposite ways. The finding that upregulated genes in cells expressing the hyperacetylation K159/298Q-C/EBPα mutant fall into different GOterm categories compared to those induced by the hypoacetylation K159/298R-C/EBPα mutant supports such a scenario.
The C/EBPα acetylation switch involving p300 and SIRT1 is reminiscent to the acetylation of C/EBPε regulated by these same factors (Bartels et al., 2015) . C/EBPε is exclusively expressed in myeloid cells and acetylation of two lysines (K121 and K198) is indispensable for C/EBPε induced terminal neutrophil differentiation. C/EBPε-K121 is homologous to K159 of C/EBPα and both are subject of sumoylation and C/EBPε-K198
is homologues to K276 that we found acetylated in C/EBPα, further supporting the similarities in the acetylation of both proteins. In compliance with our results p300mediated acetylation of C/EBPε enhances transactivation of a C/EBP-binding site containing M-CSFR-promoter reporter and the acetylation status does not affects cellular localization of C/EBPε. In contrast to our findings obtained with deacetylated C/EBPα, non-acetylated C/EBPε mutations are shown to reduce DNA binding, however, DNA-binding of wt C/EBPε upon co-transfection with p300 or SIRT1 was not investigated (Bartels et al., 2015) .
It has been shown earlier that C/EBPα expression is essential for mitochondrial biogenesis and proper expression of both nuclear and mitochondrial-genome encoded genes in brown fat (Carmona et al., 2002) . Our report shows that this function of C/EBPα depends on the hypoacetylated state of C/EBPα that is provided by the energy sensing deacetylase SIRT1, suggesting that C/EBPα mediates effects of SIRT1 on mitochondrial function. This is corroborated by the finding that the reduction of glucose concentration can induce mitochondrial respiration in wt C/EBPα expressing cells but not in cells expressing either the acetylation mimicking K159/298Q-C/EBPα mutant or the hypoacetylated K159/298R-C/EBPα mutant; while K159/298R mutant has already increased mitochondrial respiration at high glucose concentrations compared to wt C/EBPα the respiration stays at a low level in the K159/298Q mutant expressing cells.
SIRT1 is known to control mitochondrial biogenesis and gene expression by deacetylating the transcriptional coactivator peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1α) (Houtkooper et al., 2012; Rodgers et al., 2005; Gerhart-Hines et al., 2007; Nemoto et al., 2005) . In addition, SIRT1 controls the acetylation and function of forkhead box O (FOXO) transcription factors, which are important regulators of lipid and glucose metabolism as well as of stress responses (Houtkooper et al., 2012; Brunet et al., 2004; Motta et al., 2004; van der Horst et al., 2004) . SIRT1 regulates adiponectin gene expression through stimulation of a FOXO1-C/EBPα transcriptional complex (Qiao and Shao, 2006) . Here, FOXO1 is thought to be the target and deacetylated by SIRT1, however, deacetylation of C/EBPα was not investigated in this study. By using a hypoacetylation (K159/298R) mutant we demonstrate that C/EBPα deacetylation alone is sufficient for stimulating or triple K298Q/K302Q/K326Q mutants that all reside in the bZIP DNA-binding domain (Bararia et al., 2016) . Importantly, they report that single acetylation mimicking mutants of one of the three lysines show no effect on DNA binding and transactivation. In our mass spectrometry analysis K298Q, K302Q and K326Q were not covered. K298 is predicted to be acetylated by p300 and deacetylated by SIRT1 (Table S1 ) and was identified as p300 acetylation site by using Ac-K298 specific antibodies. We did not include K302 and K326 since these are not predicted as targets for p300 or SIRT1 (Table S1 ). Here we examined the dual K159Q/K298Q mutation of which K159 lies outside the bZIP domain. Since we also do not see any effect on DNA binding with co-transfection of p300 and rather a stimulation of reporter promoter activity, we believe that at least in the experimental systems we use acetylation of C/EBPα does not alter DNA-binding. Bararia et al (Bararia et al., 2016) found that cotransfection of p300 and C/EBPα results in stimulation of a C/EBP-binding site reporter, while co-transfection with GCN5 represses the reporter. Similar to these results and to other studies (Erickson et al., 2001; Bararia et al., 2016) we also found that co-expression of p300 and C/EBPα stimulates a C/EBP-dependent promoter reporter, however, in our system GCN5 did not alter the reporter activation in a dose dependent manner (although GCN5 binds C/EBPα). Possibly, in different cellular systems acetylation of C/EBPα can occur at different lysine residues by different KATs with different outcomes on DNA binding and / or transactivation. Different KAT regulatory pathways, C/EBPα interacting proteins or other posttranslational modifications of C/EBPα might influence this process. Overall, our data are more in agreement with the effects of acetylation and deacetylation of C/EBPε by p300 and SIRT1 (Bartels et al., 2015) , as was discussed above.
C/EBPα is subject of extensive PTMs, including phosphorylation, methylation, sumoylation and ubiquitination (Leutz et al., 2011; Nerlov, 2008) . Sumoylation of C/EBPα at lysine residue K159 reduces C/EBPα-transactivation of the albumin gene in fetal primary hepatocytes and abrogates the interaction with Brahma-Related Gene-1 (BRG1) resulting in reduced inhibitory effect on cell proliferation (Kim et al., 2002; Sato et al., 2006) . Acetylation and sumoylation at K159 are obviously mutually exclusive and prevention of sumoylation by acetylation could be involved in the observed higher transcriptional efficacy of the K159Q mutant measured with the C/EBP-binding site reporter. However, the K159R that similarly prevents sumoylation at this site shows no enhanced activity, suggesting that lysine-acetylation modulates the transcriptional activity of C/EBPα through other mechanisms.
Taken together our results suggest that C/EBPα acetylation depends on nutrient (glucose) availability and is negatively controlled by the class III lysine deacetylase SIRT1. Our observations that hypoacetylation mimicking C/EBPα mutant expressing cells show increased expression of mitochondrial genes, higher mitochondrial mass and mitochondrial respiration propose C/EBPα as critical downstream mediator of SIRT1 mitochondrial function.
MATERIALS AND METHODS
DNA constructs
The pcDNA3-based full-length (p42) rat C/EBPα and rat C/EBPα-FLAG have been described earlier (Muller et al., 2010) 
Cell culture, transfection and immunofluorescence
All cells were cultured in DMEM plus 10% FCS (Invitrogen) and penicillin/streptomycin at 5% CO2 and 37° C. HEK293T cells were seeded at 2.5 × 10 6 cell in 10 cm dishes and transfected the next day with 5 µg expression vectors using calcium phosphate. Immunofluorescence staining protocol was described previously (Muller et al., 2010) . The primary antibodies used were anti-C/EBPα (14AA, Santa Cruz Biotechnology), anti-FLAG (M2, #F3165, Sigma) and anti-HA (#MMS-101R, Convace).
Secondary antibodies used were Alexa Fluor 488 or 568 conjugated (Invitrogen). p300
inhibitor C646 (CAS 328968-36-1; Sigma-Aldrich) was used at final concentration of 10 μM.
Co-immunoprecipitation
Co-immunoprecipitation was performed as described previously by (Muller et al., 2010) . Anti-C/EBPα (14AA, Santacruz), anti-FLAG (M2, #F3165, Sigma), anti-HA (#MMS-101R, Convace) and anti-Tip60 (#NBP2-20647, Novus Biologicals) were used for precipitation as indicated. To detect the acetylation of C/EBPα in Fao cells, endogenous level, or in transiently transfected HEK293T cells, the cells were treated with the deacetylase inhibitors 1 µM TSA (#T8552, Sigma) and 5 mM nicotinamide (#47865U, Sigma) 8 h before harvesting. The IP lysis buffer and IP wash buffer were supplemented with these inhibitors as well.
Immunoblotting
Western blotting was performed following a general protocol. The following antibodies were used: anti-C/EBPα ( 
Luciferase assay
The luciferase construct containing two consensus C/EBPα binding sites site (pM82;
lacking the AP-1 binding site) was described earlier (Sterneck et al., 1992 
In vitro deacetylation
In vitro deacetylation assay was performed as described by (Li et al., 2008) . Acetylated C/EBPα was obtained by co-transfecting HEK293T cells with C/EBPα-FLAG and p300 expression plasmids. Cells were treated with 10 µM TSA and 5 mM nicotinamide 8 h before harvest. Anti-FLAG M2 beads (#M8823, Sigma) were used for precipitation and 3X-FLAG peptide (F4799, Sigma) was used for elution.
Lentiviral transduction and cumate-inducible system
Hepa1-6 cells were infected with SparQ All-in-one Cumate Switch Vector (#QM812B-1, System Bioscience Inc) containing either wt rC/EBPα-FLAG cDNA, K159/298Q-rC/EBPα-FLAG cDNA, K159/298R-rC/EBPα-FLAG cDNA or empty vector and propagated under puromycin selection (1.5 μg/ml). Cumate-inducing solution was added to the cells at a dilution (1:1000) 3 days before any experiment. To obtain the C/EBPα-KD Hepa1-6 cells, the cells were infected with pLKO.1 lentiviral constructs containing shRNAs against mouse C/EBPα: sh:5'-CCG GCA ACG CAA CGT GGA GAC GCA ACT CGA GTT GCG TCT CCA CGT TGC GTT GTT TTT-3' or non-target shRNA control (Sigma-Aldrich) and propagated under puromycin selection (1.5 μg/ml).
Electrophoretic Mobility Shift Assay (EMSA)
HEK293T cells were transfected with expression vectors by the calcium phosphate method. Anti-FLAG M2 beads (#M8823, Sigma) were used for precipitating C/EBPα- 
Measurement of oxygen consumption rate (OCR)
Oxygen consumption rates (OCR) extracellular acidification rates and (ECAR) were determined using a Seahorse XF96 Extracellular Flux analyzer (Seahorse Bioscience).
2.5 × 10 4 of cumate-induced Hepa1-6 cells per well were seeded into a 96-well XF cell culture microplate 24 h prior to the assay, see the Supplemental Experimental Procedures.
Mass Spectrometry analysis
HEK293T cells were transiently transfected with C/EBPα and p300-HA expression vectors. C/EBPα was immunoprecipitated using rabbit anti-C/EBPα antibody followed SDS-PAGE and the proper C/EBPα protein band cut and used for further MS protocol, see the Supplemental Experimental Procedures.
RNA-seq Analysis
Transcriptome analysis was done in triplicates. Hepa1-6 cells treated for three days with cumate solution to express wt-, K159/298Q-and K159/298R-C/EBPα proteins were harvested and the total RNAs were isolated using RNeasy Plus mini Kit (#74136,
Qiagen) according to the manufacturer's protocol, see the Supplemental Experimental
Procedures.
Quantitative Real-Time PCR analysis
Total RNA was isolated using the RNeasy Kit (QIAGEN). For cDNA synthesis 1μg RNA was reverse transcribed with the Transcriptor First Strand cDNA Synthesis Kit (Roche)
using Oligo(d)T primers. qRT-PCR was performed using the LightCycler® 480 SYBR Green I Master Mix (Roche). Primer pairs are listed in Table S3 .
Chromatin and reporter C/EBP-binding site immunoprecipitation
HEK293T cells were transfected with wt-, K159/298Q-or K159/298R-C/EBPα expression vectors for the chromatin IP. HEK293T cells were cotransfected with C/EBP-binding site reporter construct and wt-, K159/298Q-or K159/298R-C/EBPα-FLAG expression vectors for the C/EBP-binding site IP. ChIP assay was performed with 5 × 10 6 cells using a Bioruptor (Diagenode, Inc.) for sonication (details on request). ChIP antibodies were against FLAG (M2, #F3165, Sigma) and non-specific mouse IgG from Santa Cruz Biotechnology. The fold enrichment was calculated relative to the background detected with non-specific rabbit IgG. For the semi-quantitative PCR, 1/50 (1 μl) of DNA obtained from the ChIP assay was used as template in a PCR reaction with 28 cycles. Primer pairs are listed in Table S3 .
Mitochondrial content and mtDNA copy mumber
Mitochondrial mass was measured using MitoTracker Red 480 kit following the manufacturer's protocol (#M22425, ThermoFisher). Fluorescence was measured using a GloMax-Multi Detection System (Promega). SIRT1 Activator II (CAS 374922-43-7;
Merck #566313) was used at final concentration of 10 µM. Mitochondrial DNA was copurified with genomic DNA from Hepa1-6 cells using standard protocol, Ct values determined for cytochrome b gene encoded by mtDNA and β-actin gene encoded by the nuclear DNA, and the relative mtDNA copy number calculated by normalizing to β-actin gene copy number. Primer pairs are listed in Table S3 .
Mice C57BL/6 male mice were housed individually at a standard 12-h light/dark cycle at 22°C in a pathogen free animal facility and were used for all experiments. Numbers of mice used in the separate experiments can be retrieved from the figure legends. Single caged mice of 3 months of age were fed ad libitum or fed calorie restricted (70% of normal food intake) for 4 weeks. For the other experiment mice were fed high fat diet or normal control diet (Research Diets Inc., product D12492: 60% Fat, 20%
Carbohydrates, 20% protein; control diet D12450B, 10% fat, 70% Carbohydrates, 20%
Protein) for 20 weeks. Mice were sacrificed by isoflurane at the end of each study. All animal experiments were performed in compliance with protocols approved by the Institutional Animal Care and Use Committee.
Statistics
Data were analyzed by two-tailed independent-sample Student's t test for comparisons between two different groups and expressed as mean ± SD. The data met the assumptions of this test. Differences were considered to be significant when p < 0.05. RNA-seq Analysis section contains details of its used statistical methods. No statistical methods were used to determine sample size, and randomization was not used for analyses.
Supplemental item titles and legends
Supplemental Information includes Supplemental Figures 1-4 , Supplemental Tables 1-3 and Supplemental Experimental Procedures and can be found with this article online at
Accession Numbers
Transcriptome RNA-sequencing data were deposited at ArrayExpress with accession number E-MTAB-6323.
